Relatlimab Explained
| Type: | mab |
| Mab Type: | mab |
| Source: | u |
| Target: | Lymphocyte activation gene-3 (LAG-3) |
| Dailymedid: | Relatlimab |
| Routes Of Administration: | Intravenous |
| Class: | Antineoplastic |
| Atc Prefix: | None |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | [1] |
| Legal Us: | Rx-only |
| Legal Us Comment: | only in combination with nivolumab |
| Cas Number: | 1673516-98-7 |
| Drugbank: | DB14851 |
| Unii: | AF75XOF6W3 |
| Kegg: | D11350 |
| Synonyms: | BMS-986016, relatlimab-rmbw |
| C: | 6472 |
| H: | 9922 |
| N: | 1710 |
| O: | 2024 |
| S: | 38 |
Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[2] [3] It is used in combination with nivolumab to treat melanoma.
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.[4] It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary cells.
History
, relatlimab is undergoing Phase II/III trials.
The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.[5]
Names
Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).[6] [7] [8]
Notes and References
- Web site: Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22] ]. . 22 December 2023 . 3 January 2024.
- Book: Cavagnaro JA, Cosenza ME . Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals . 2021 . CRC Press . Boca Raton, Florida . 978-1-00-047185-4.
- Robert C . LAG-3 and PD-1 blockade raises the bar for melanoma. . Nature Cancer . December 2021 . 2 . 12 . 1251–3 . 10.1038/s43018-021-00276-8 . 35121906 . 245407697 .
- Web site: Opdualag- nivolumab and relatlimab-rmbw injection . DailyMed . 18 March 2022 . 22 March 2022.
- U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma . . Business Wire . 18 March 2022 . 19 March 2022.
- Web site: Relatlimab . American Medical Association . 22 March 2022.
- http://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Frelatlimab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab
- ((World Health Organization)) . 2019 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81 . WHO Drug Information . 33 . 1 . 10665/330896 . free . World Health Organization .
